Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

Clinical trial NCT05486013 · UNKNOWN

Trial details

NCT number: NCT05486013
Sponsor: Peking University Third Hospital
Status: UNKNOWN
Study type: OBSERVATIONAL

Mantle Cell Lymphoma

Start date: 2022-05-26
Primary completion: 2025-05-26
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.